MRNA vs TECH

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Oct 22, 2026

MRNA

35.2
AI Score
VS
TECH Wins

TECH

60.9
AI Score

Investment Advisor Scores

MRNA

Oct 22, 2026
35score
Recommendation
AVOID NEW MONEY

TECH

Oct 22, 2026
61score
Recommendation
HOLD

AI Analyst Insights

Detailed Metrics Comparison

Metric MRNA TECH Winner
Forward P/E 23.0415 34.6021 MRNA
PEG Ratio 0 2.1116 Tie
Revenue Growth 2.1% 1.3% MRNA
Earnings Growth -85.1% 128.6% TECH
Tradestie Score 35.2/100 60.9/100 TECH
Profit Margin -141.4% 15.0% TECH
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation AVOID NEW MONEY HOLD Tie

Relative Price Performance (Last 90 Days)

MRNA 1M: +11.3% · 3M: +274.8% TECH 1M: +0.1% · 3M: +1.4%

Current Technical Phase

MRNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (56.8% over 20 days), RSI 51

RSI (14): 51.0 · Price: $202.63

TECH

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 57.7 · Price: $72.62

Fundamentals Snapshot

Metric MRNA TECH
Market Cap — —
Forward P/E -42.4 42.7
Trailing P/E — 62.6
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin -0.7% 0.7%
Operating Margin -5.6% 0.3%
EPS -8.10 1.16
Dividend Yield — 0.00%

Frequently Asked Questions

Based on our detailed analysis, TECH is currently the stronger investment candidate, winning 3 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.